Literature DB >> 14152273

COMPARATIVE CLINICAL TOXICITY OF 6-MERCAPTOPURINE (NSC-755)-1 AND 6-MERCAPTOPURINE RIBONUCLEOSIDE (NSC-4911)-2 ADMINISTERED INTRAVENOUSLY TO PATIENTS WITH ADVANCED CANCER.

W REGELSON, J F HOLLAND, E FREI, G L GOLD, T HALL, M KRANT, S O MILLER.   

Abstract

Entities:  

Keywords:  BONE MARROW; EXPERIMENTAL LAB STUDY; INJECTIONS, INTRAVENOUS; LEUKOPENIA; MERCAPTOPURINE; MICE; NUCLEOSIDES; PHARMACOLOGY; PURINES; PYRIMIDINES; THROMBOPENIA; TOXICOLOGIC REPORT

Mesh：

Substances：

Year:  1964        PMID： 14152273

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN： 0069-0112


× No keyword cloud information.
  2 in total

1.  A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors.

Authors:  P C Adamson; S Zimm; A H Ragab; S M Steinberg; F Balis; B A Kamen; T J Vietti; A Gillespie; D G Poplack
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 2.  Cancer metabolism: strategic diversion from targeting cancer drivers to targeting cancer suppliers.

Authors:  Soo-Youl Kim
Journal:  Biomol Ther (Seoul)       Date:  2015-03-01       Impact factor: 4.634
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.